Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alterity Therapeutics ( (AU:ATH) ) has provided an update.
Alterity Therapeutics Limited has responded to a price query from the ASX regarding a recent increase in its share price and trading volume. The company stated it is unaware of any undisclosed information that could explain the trading activity. However, it highlighted upcoming data releases from its Phase 2 studies and an investor roadshow as potential factors influencing market anticipation.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on the development of therapeutic drugs for neurodegenerative diseases. The company is engaged in advancing clinical trials and is currently working on Phase 2 studies for its drug candidates ATH-201 and ATH-202.
YTD Price Performance: 50.0%
Average Trading Volume: 14,643,882
Technical Sentiment Signal: Sell
Current Market Cap: A$136.9M
See more data about ATH stock on TipRanks’ Stock Analysis page.